Overview

This trial has been completed.

Condition healthy
Sponsor University of Utah
Start date December 2011
End date September 2016
Trial size 28 participants
Trial identifier NCT01669590, IRB_00050933

Summary

The goal of the research project is to determine how aging and inactivity reduce the muscle anabolic effect of nutrients and lead to muscle and functional loss. The central hypothesis is that aging reduces mTORC1 signaling and the expression of skeletal muscle amino acid transporters in response to anabolic stimulation leading to reduced muscle adaptation to increased intracellular amino acid requirements. The investigators further hypothesize that inactivity exacerbates this effect with significant muscle and functional loss, and rehabilitation restores muscle signaling, metabolism and function to baseline values.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Arm

Primary Outcomes

Measure
amino acid transporter
time frame: before and after (1 and 3h) amino acid ingestion. These samples will be taken before bed rest and 7 days after bed rest.

Eligibility Criteria

Male or female participants from 18 years up to 75 years old.

Inclusion Criteria: 1 . Age between 18-35 and 60-75 yrs 2. Ability to sign informed consent 3. Mini-mental state exam score >26 4. Free-living, prior to admission Exclusion Criteria: 1. Cardiac abnormalities considered exclusionary by the study physician (e.g., CHF, CAD, right-to-left shunt) 2. Uncontrolled endocrine or metabolic disease (e.g., hypo/hyperthyroidism, diabetes) 3. GFR <65 mL/min/1.73m2 or evidence of kidney disease or failure 4. Vascular disease or risk factors of peripheral atherosclerosis. (e.g., uncontrolled hypertension, obesity, diabetes, hypercholesterolemia > 250 mg/dl, claudication or evidence of venous or arterial insufficiency upon palpitation of femoral, popliteal and pedal arteries) 5. Risk of DVT including family history of thrombophilia, DVT, pulmonary emboli, myeloproliferative diseases including polycythemia (Hb>18 g/dL) or thrombocytosis (platelets>400x103/mL), and connective tissue diseases (positive lupus anticoagulant), hyperhomocysteinemia, deficiencies of factor V Leiden, proteins S and C, and antithrombin III 6. Use of anticoagulant therapy. (e.g., Coumadin, heparin) 7. Prior history of Heparin-Induced Thrombocytopenia (HIT) 8. Elevated systolic pressure >150 or a diastolic blood pressure > 100 9. Implanted electronic devices (e.g., pacemakers, electronic infusion pumps, stimulators) 10. Cancer or history of successfully treated cancer (less than 1 year) other than basal cell carcinoma 11. Currently on a weight-loss diet or body mass index > 30 kg/m2 12. Inability to abstain from smoking for duration of study 13. A history of > 20 pack per year smoking 14. HIV or hepatitis B or C* 15. Recent anabolic or corticosteroids use (within 3 months) 16. Subjects with hemoglobin or hematocrit lower than accepted lab values 17. Agitation/aggression disorder (by psychiatric history and exam) 18. History of stroke with motor disability 19. A recent history (<12 months) of GI bleed 20. Pregnancy as determined by a pregnancy test 21. Depression [>5 on the 15 items Geriatric Depression Scale (GDS)] 22. Alcohol or drug abuse 23. Exercise training (>1 session of moderate to high intensity aerobic or resistance exercise/week) 24. Liver disease (AST/ALT 2 times above the normal limit, hyperbilirubinemia) 25. Respiratory disease (acute upper respiratory infection, history of chronic lung disease with resting oxygen saturation <97% on room air) 26. Any other condition or event considered exclusionary by the PI and faculty physician

Additional Information

Official title Nutrient Regulation of Amino Acid Transporters in Aging Human Skeletal Muscle
Trial information was received from ClinicalTrials.gov and was last updated in November 2016.
Information provided to ClinicalTrials.gov by University of Utah.